| Name | Calcium dobesilate |
| Description | Calcium dobesilate(CaD) has angioprotective properties and protects endothelial cells partly by ameliorating HG induced inflammation. |
| Cell Research | HUVECs were seeded in 96-well culture plates (1×10^4 cells/well). Following 24 h, the control or experimental medium was added. At 12, 24, 48 and 72 h, 10 μl CCK-8 reagent was added to each well for 1 h. Absorbance values were recorded at a wavelength of 450 nm using a microplate reader[1]. |
| In vitro | CaD inhibited abnormal cell proliferation. high glucose (HG) treatment also significantly enhanced HVUEC migration compared to the control treatment. In contrast, CaD treatment partially inhibited HUVEC migration compared to HG exposure. HG?treated HUVECs exhibited increased FITC?BSA permeability compared to control cells cultured in medium alone; however, CaD application prevented the HG?induced increase in FITC?BSA permeability and suppressed HG?induced overexpression of endothelial markers (VEGF, VEGFR?2, endocan) and inflammation markers (ICAM?1, MCP?1, PTX3) in HUVECs. CaD has angioprotective properties and protects endothelial cells partly by ameliorating HG?induced inflammation[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (218.15 mM)
|
| Keywords | Apoptosis | inhibit | Inhibitor | Calcium dobesilate |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| Related Compound Libraries | Apoptosis Compound Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library |
United States
